3-(Cyclopropylmethyl)-7-((4-(4-[

Animals Brain / metabolism Carbon Radioisotopes / chemistry Contrast Media / chemical synthesis Male Positron-Emission Tomography Pyridines / chemical synthesis Radiopharmaceuticals / chemical synthesis Rats, Sprague-Dawley Receptors, Metabotropic Glutamate / metabolism Triazoles / chemical synthesis
Autoradiography Carbon-11 Metabotropic glutamate receptor 2 (mGluR2) Positron emission tomography (PET) Schizophrenia

Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 28 07 2020
revised: 06 09 2020
accepted: 11 09 2020
pubmed: 18 9 2020
medline: 3 7 2021
entrez: 17 9 2020
Statut: ppublish

Résumé

Selective metabotropic glutamate receptor 2 (mGluR2) inhibitors have been demonstrated to show therapeutic effects by improving alleviating symptoms of schizophrenic patients in clinical studies. Herein we report the synthesis and preliminary evaluation of a

Identifiants

DOI: 10.1016/j.bmcl.2020.127555 PMID: 32941990
pubmed: 32941990
pii: S0960-894X(20)30666-1
doi: 10.1016/j.bmcl.2020.127555
pii:
doi:

Substances chimiques

Carbon Radioisotopes 0
Carbon-11 0
Contrast Media 0
Pyridines 0
Radiopharmaceuticals 0
Receptors, Metabotropic Glutamate 0
Triazoles 0
metabotropic glutamate receptor 2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

127555

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Katsushi Kumata (K)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.

Yiding Zhang (Y)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.

Masanao Ogawa (M)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan; SHI Accelerator Service, Ltd, 1-17-6 Osaki, Shinagawa-ku, Tokyo 141-0032, Japan.

Yusuke Kurihara (Y)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan; SHI Accelerator Service, Ltd, 1-17-6 Osaki, Shinagawa-ku, Tokyo 141-0032, Japan.

Wakana Mori (W)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.

Kuan Hu (K)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.

Masayuki Fujinaga (M)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.

Nobuki Nengaki (N)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan; SHI Accelerator Service, Ltd, 1-17-6 Osaki, Shinagawa-ku, Tokyo 141-0032, Japan.

Ming-Rong Zhang (MR)

Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. Electronic address: zhang.ming-rong@qst.go.jp.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Produits chimiques inorganiques › Isotopes › Radio-isotopes › Radio-isotopes du carbone › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits de contraste › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Sprague-Dawley › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs aux acides aminés › Récepteurs au glutamate › Récepteurs métabotropes au glutamate › 3-(Cyclopropylmethyl)-7-((4-(4-[
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › 3-(Cyclopropylmethyl)-7-((4-(4-[